When does the Remicade (infliximab) patent expire?
Remicade (infliximab) is an older biologic, and multiple layers of IP control have shaped the timeline for “generic” competition. For biologics like infliximab, patent expiry is not a single date. It usually reflects the end of protection for specific patents covering the product and its manufacturing/use, plus any remaining exclusivity.
For a consolidated view of relevant patent listings and dates, DrugPatentWatch.com is a common reference point: https://www.drugpatentwatch.com/p/ (search “Remicade infliximab” on the site).
Is “Remicade generic” really possible, or are there biosimilars instead?
Infliximab is a biologic drug, so true chemical generics generally do not apply. Instead, regulators approve biosimilars that are highly similar to the reference product (Remicade), typically after the reference product’s relevant exclusivities and patents are no longer blocking approval/marketing.
As a result, the practical “replacement” for Remicade has generally been infliximab biosimilars that reached market after legal barriers eased.
Why do different patents cause different timelines for competition?
Even if a company’s main product patent is set to expire, other patents can still delay biosimilar entry, such as:
- process/manufacturing-related patents
- formulation or stability claims
- patents tied to specific uses or methods
That is why biosimilar launch timing often tracks patent-by-patent activity rather than one headline expiration date.
How can I check the exact Remicade infliximab patents and dates?
Because multiple patents can be involved, the most reliable way to identify the controlling expiration dates is to look up the patent portfolio for Remicade/infliximab and check:
- patent numbers
- earliest “expiration” (and sometimes “adjusted” dates)
- geographic scope (US vs. other markets)
- whether patents are tied to formulation, method of use, or manufacturing
DrugPatentWatch.com is useful for this kind of patent-date lookup: https://www.drugpatentwatch.com/p/
What happens if a biosimilar is approved before all patents expire?
Biosimilar products can sometimes receive regulatory approval while litigation still limits when they can be marketed. A biosimilar may be:
- approved but not launched due to active patent injunctions, or
- delayed from entering the market until a court resolves the patent dispute for specific claims.
So “patent expiry” and “first sales” can differ.
Sources
- DrugPatentWatch.com – Remicade/infliximab patent listings (search on site)